We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.43%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$240M
Cap. Flow
+$114M
Cap. Flow %
4.13%
Top 10 Hldgs %
48.06%
Holding
144
New
27
Increased
15
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$58.4M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$54.6M
3
JNJ icon
Johnson & Johnson
JNJ
+$45.1M
4
ALKS icon
Alkermes
ALKS
+$27.4M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$24.1M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$72.5M
2
GILD icon
Gilead Sciences
GILD
+$21.9M
3
PRGO icon
Perrigo
PRGO
+$21.6M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$19.4M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$9.46M

Sector Composition

Rank Sector Weight
1 Healthcare 84.12%
2 Real Estate 3.08%
3 Financials 1.53%
4 Technology 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
126
CALL
Sarepta Therapeutics
SRPT
$1.64B
– –
-115,100
Closed -$1.53M
SRPT icon
127
Sarepta Therapeutics
SRPT
$1.64B
– –
-230,300
Closed -$3.06M
INFI
128
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-438,623
Closed -$6.13M
SRNE
129
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-142,597
Closed -$1.65M
ALXN
130
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-77,200
Closed -$13.4M
IMMU
131
DELISTED
Immunomedics Inc
IMMU
– –
-500,000
Closed -$1.92M
MNTA
132
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-353,575
Closed -$5.37M
ACHN
133
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-547,300
Closed -$5.4M
ATHN
134
CALL
DELISTED
Athenahealth, Inc.
ATHN
– –
-23,100
Closed -$2.76M
ATHN
135
DELISTED
Athenahealth, Inc.
ATHN
– –
-23,100
Closed -$2.76M
KITE
136
CALL
DELISTED
Kite Pharma, Inc.
KITE
– –
-46,500
Closed -$2.68M
GEVA
137
CALL
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-71,000
Closed -$6.92M
GEVA
138
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-198,689
Closed -$19.4M
ACT.PRA
139
DELISTED
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
– –
-5,000
Closed -$5.06M
2 3 4 5
6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Tekla Capital Management held 144 positions worth $2.76B, up 9.5% from $2.52B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Tekla Capital Management deployed $114M of net new capital in Q2 2015, opening 27 new positions and adding to 15 existing holdings. Its largest new stake was Humana: 112,000 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was AbbVie, an estimated $72.5M trimmed.

  • Tekla Capital Management's largest Q2 2015 buy was Humana: 112,000 shares worth $21.4M.
  • Tekla Capital Management added most to Viatris in Q2 2015, an estimated $58.4M increase.
  • Tekla Capital Management's biggest Q2 2015 reduction was AbbVie, cutting an estimated $72.5M.
  • Tekla Capital Management fully exited Perrigo in Q2 2015, selling an estimated $21.6M.
  • Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q2 2015.
  • Tekla Capital Management opened 27 new positions and closed 28 in Q2 2015.
  • Tekla Capital Management's portfolio value rose 9.5% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.